ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE